Kepivance Approval History 
- FDA approved: Yes (First approved December 15th, 2004)
- Brand name: Kepivance
- Generic name: palifermin
- Company: Amgen Inc.
- Treatment for: Mucositis
Kepivance (palifermin) is a recombinant human keratinocyte growth factor indicated to decrease the incidence and duration of severe oral mucositis.
FDA Approval History for Kepivance
| Date | Article |
|---|---|
| Dec 15, 2004 |  Kepivance Amgen Inc. - Treatment for Severe Oral Mucositis in Cancer Patients |
| Jun 24, 2004 | Amgen Submits Biologics License Application for FDA Approval of Palifermin |
See also...
Kepivance (palifermin) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
